Browse KRT6A

Summary
SymbolKRT6A
Namekeratin 6A, type II
Aliases CK6C; CK6D; K6D; KRT6D; keratin 6D; keratin 6A; keratin 6A, , type II; CK6A; K6A; KDAMP; cytokeratin 6A; cyt ......
Chromosomal Location12q13.13
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Basic function annotation.
> Subcellular Location, Domain and Function
> Gene Ontology
> KEGG and Reactome Pathway
> Subcellular Location, Domain and Function
 
Subcellular Location -
Domain PF00038 Intermediate filament protein
PF16208 Keratin type II head
Function

Epidermis-specific type I keratin involved in wound healing. Involved in the activation of follicular keratinocytes after wounding, while it does not play a major role in keratinocyte proliferation or migration. Participates in the regulation of epithelial migration by inhibiting the activity of SRC during wound repair.

> Gene Ontology
 
Biological Process GO:0045103 intermediate filament-based process
GO:0045104 intermediate filament cytoskeleton organization
Molecular Function -
Cellular Component GO:0005882 intermediate filament
GO:0045095 keratin filament
GO:0045111 intermediate filament cytoskeleton
> KEGG and Reactome Pathway
 
KEGG -
Reactome R-HSA-1266738: Developmental Biology
R-HSA-6805567: Keratinization
Summary
SymbolKRT6A
Namekeratin 6A, type II
Aliases CK6C; CK6D; K6D; KRT6D; keratin 6D; keratin 6A; keratin 6A, , type II; CK6A; K6A; KDAMP; cytokeratin 6A; cyt ......
Chromosomal Location12q13.13
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Literatures that report relations between KRT6A and anti-tumor immunity. The specific mechanism were also collected if the literature reports that a gene specifically promotes or inhibits the infiltration or function of T/NK cells.
> Text Mining
 

There is no record.

Summary
SymbolKRT6A
Namekeratin 6A, type II
Aliases CK6C; CK6D; K6D; KRT6D; keratin 6D; keratin 6A; keratin 6A, , type II; CK6A; K6A; KDAMP; cytokeratin 6A; cyt ......
Chromosomal Location12q13.13
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content High-throughput screening data (e.g. CRISPR-Cas9, shRNA and RNAi) for T cell-mediated killing. Genetic screen techniques can identify mechanisms of tumor cell resistance (e.g., PTPN2) and sensitivity (e.g., APLNR) to killing by cytotoxic T cells, the central effectors of anti-tumor immunity. After comprehensively searching, eight groups of screening data sets were collected in the current database. In this tab, users can check whether their selected genes cause resistance or increase sensitivity to T cell-mediated killing in various data sets.
> High-throughput Screening
  Statistical results of KRT6A in screening data sets for detecting immune reponses.
PMID Screening System Cancer Type Cell Line Data Set Statistical Results Relation to immunity
29301958CRISPR-Cas9 melanomaB16F10Pmel-1 T cell NA/NSNA/NS
29301958CRISPR-Cas9 melanomaB16F10OT-1 T cell NA/NSNA/NS
28783722CRISPR-Cas9 melanomaMel6242CT-CRISPR NA/NSNA/NS
28723893CRISPR-Cas9 melanomaB16GVAX+Anti-PD1 NA/NSNA/NS
28723893CRISPR-Cas9 melanomaB16GVAX NA/NSNA/NS
25691366RNAiBreast cancerMCF7Luc-CTL assay NA/NSNA/NS
24476824shRNAmelanomaB16Primary screen NA/NSNA/NS
24476824shRNAmelanomaB16Secondary screen NA/NSNA/NS
Summary
SymbolKRT6A
Namekeratin 6A, type II
Aliases CK6C; CK6D; K6D; KRT6D; keratin 6D; keratin 6A; keratin 6A, , type II; CK6A; K6A; KDAMP; cytokeratin 6A; cyt ......
Chromosomal Location12q13.13
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Transcriptomic and genomic profiling of pre-treated tumor biopsies from responders and non-responders to immunotherapy. These data were used to identify signatures and mechanisms of response to checkpoint blockade (e.g., anti-PDL1 and anti-PD1). One example is that mutations in the gene PBRM1 benefit clinical survival of patients with clear cell renal cell carcinoma. After comprehensively searching, we collected 5 and 6 of transcriptomic and genomic data sets, respectively. In this tab, users can check whether their selected genes have significant difference of expression or mutation between responders and non-responders in various data sets.
> Expression difference between responders and non-responders
> Mutation difference between responders and non-responders
> Expression difference between responders and non-responders
 
Points in the above scatter plot represent the expression difference of KRT6A in various data sets.
No PMID Cancer type Group Drug # Res # NRes Log2 (Fold Change) P value Anno
126997480MelanomaallAnti-PD-1 (pembrolizumab and nivolumab)14121.1820.283
226997480MelanomaMAPKiAnti-PD-1 (pembrolizumab and nivolumab)65-0.2770.873
326997480Melanomanon-MAPKiAnti-PD-1 (pembrolizumab and nivolumab)872.2820.114
428552987Urothelial cancerallAnti-PD-L1 (atezolizumab) 9160.120.922
528552987Urothelial cancersmokingAnti-PD-L1 (atezolizumab) 591.6190.496
628552987Urothelial cancernon-smokingAnti-PD-L1 (atezolizumab) 47-1.7730.545
729033130MelanomaallAnti-PD-1 (nivolumab) 2623-1.6380.232
829033130MelanomaNIV3-PROGAnti-PD-1 (nivolumab) 1511-3.1610.126
929033130MelanomaNIV3-NAIVEAnti-PD-1 (nivolumab) 1112-0.0060.998
1029301960Clear cell renal cell carcinoma (ccRCC)allAnti-PD-1 (nivolumab) 480.9210.173
1129301960Clear cell renal cell carcinoma (ccRCC)VEGFRiAnti-PD-1 (nivolumab) 2001
1229301960Clear cell renal cell carcinoma (ccRCC)non-VEGFRiAnti-PD-1 (nivolumab) 281.8420.0386
1329443960Urothelial cancerallAnti-PD-L1 (atezolizumab) 68230-0.5810.319
> Mutation difference between responders and non-responders
 
Points in the above scatter plot represent the mutation difference of KRT6A in various data sets.
No PMID Cancer type Group Drug # Res # NRes % Mut/Res % Mut/NRes % Diff (R vs NR) Pval Anno
125765070Non-small cell lung cancer (NSCLC)allAnti-PD-1 (pembrolizumab) 14170001
225765070Non-small cell lung cancer (NSCLC)smokingAnti-PD-1 (pembrolizumab) 1030001
325765070Non-small cell lung cancer (NSCLC)non-smokingAnti-PD-1 (pembrolizumab) 4140001
426359337MelanomaallAnti-CTLA-4 (ipilimumab) 277314.82.712.10.0439
526359337MelanomaBRAFiAnti-CTLA-4 (ipilimumab) 0140001
626359337Melanomanon-BRAFiAnti-CTLA-4 (ipilimumab) 275914.83.411.40.0746
726997480MelanomaallAnti-PD-1 (pembrolizumab and nivolumab)21174.804.81
826997480MelanomaMAPKiAnti-PD-1 (pembrolizumab and nivolumab)860001
926997480Melanomanon-MAPKiAnti-PD-1 (pembrolizumab and nivolumab)13117.707.71
1028552987Urothelial cancerallAnti-PD-L1 (atezolizumab) 9160001
1128552987Urothelial cancersmokingAnti-PD-L1 (atezolizumab) 590001
1228552987Urothelial cancernon-smokingAnti-PD-L1 (atezolizumab) 470001
1329033130MelanomaallAnti-PD-1 (nivolumab) 382707.4-7.40.169
1429033130MelanomaNIV3-PROGAnti-PD-1 (nivolumab) 22130001
1529033130MelanomaNIV3-NAIVEAnti-PD-1 (nivolumab) 1614014.3-14.30.209
1629301960Clear cell renal cell carcinoma (ccRCC)allAnti-PD-1 (nivolumab) 11130001
1729301960Clear cell renal cell carcinoma (ccRCC)VEGFRiAnti-PD-1 (nivolumab) 610001
1829301960Clear cell renal cell carcinoma (ccRCC)non-VEGFRiAnti-PD-1 (nivolumab) 5120001
Summary
SymbolKRT6A
Namekeratin 6A, type II
Aliases CK6C; CK6D; K6D; KRT6D; keratin 6D; keratin 6A; keratin 6A, , type II; CK6A; K6A; KDAMP; cytokeratin 6A; cyt ......
Chromosomal Location12q13.13
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Relations between abundance of tumor-infiltrating lymphocytes (TILs) and expression, copy number, methylation, or mutation of KRT6A. The immune-related signatures of 28 TIL types from Charoentong's study, which can be viewed in the download page. For each cancer type, the relative abundance of TILs were inferred by using gene set variation analysis (GSVA) based on gene expression profile. In this tab, users can examine which kinds of TILs might be regulated by the current gene.
> Lymphocyte
 
Summary
SymbolKRT6A
Namekeratin 6A, type II
Aliases CK6C; CK6D; K6D; KRT6D; keratin 6D; keratin 6A; keratin 6A, , type II; CK6A; K6A; KDAMP; cytokeratin 6A; cyt ......
Chromosomal Location12q13.13
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Relations between three kinds of immunomodulators and expression, copy number, methylation, or mutation of KRT6A. These immunomo-dulators were collected from Charoentong's study. In this tab, users can examine which immunomodulators might be regulated by KRT6A.
> Immunoinhibitor
> Immunostimulator
> MHC molecule
> Immunoinhibitor
 
> Immunostimulator
 
> MHC molecule
 
Summary
SymbolKRT6A
Namekeratin 6A, type II
Aliases CK6C; CK6D; K6D; KRT6D; keratin 6D; keratin 6A; keratin 6A, , type II; CK6A; K6A; KDAMP; cytokeratin 6A; cyt ......
Chromosomal Location12q13.13
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Relations between chemokines (or receptors) and expression, copy number, methylation, or mutation of KRT6A. In this tab, users can examine which chemokines (or receptors) might be regulated by the current gene.
> Chemokine
> Receptor
> Chemokine
 
> Receptor
 
Summary
SymbolKRT6A
Namekeratin 6A, type II
Aliases CK6C; CK6D; K6D; KRT6D; keratin 6D; keratin 6A; keratin 6A, , type II; CK6A; K6A; KDAMP; cytokeratin 6A; cyt ......
Chromosomal Location12q13.13
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Distribution of KRT6A expression across immune and molecular subtypes.
> Immune subtype
> Molecular subtype
> Immune subtype
 
> Molecular subtype
 
Summary
SymbolKRT6A
Namekeratin 6A, type II
Aliases CK6C; CK6D; K6D; KRT6D; keratin 6D; keratin 6A; keratin 6A, , type II; CK6A; K6A; KDAMP; cytokeratin 6A; cyt ......
Chromosomal Location12q13.13
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Associations between KRT6A and clinical features.
> Overall survival analysis
> Cancer stage
> Tumor grade
> Overall survival
 
> Stage
 
> Grade
 
Summary
SymbolKRT6A
Namekeratin 6A, type II
Aliases CK6C; CK6D; K6D; KRT6D; keratin 6D; keratin 6A; keratin 6A, , type II; CK6A; K6A; KDAMP; cytokeratin 6A; cyt ......
Chromosomal Location12q13.13
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Drugs targeting KRT6A collected from DrugBank database.
> Drugs from DrugBank database
 

  Details on drugs targeting KRT6A.
ID Name Drug Type Targets #Targets
DB01593ZincSmall MoleculeA1BG, A2M, AGT, AHSG, ALDOA, APCS, APLP1, APLP2, APOA1, APOA2, APO ......119